2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-103721
    SIRT6-IN-2 891002-11-2 99.92%
    SIRT6-IN-2 (Compound 5) is a selective and competitive SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects.
    SIRT6-IN-2
  • HY-105172
    TT-232 147159-51-1 98.72%
    TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent.
    TT-232
  • HY-108013
    Armillarisin A 53696-74-5 99.80%
    Armillarisin A has the potential for the ulcerative colitis (UC) study. Armillarisin A increases IL-4 and lower IL-1β.
    Armillarisin A
  • HY-108251
    Methotrexate metabolite

    Methotrexate metabolite

    		19741-14-1 98.44%
    Methotrexate metabolite (DAMPA) is an active metabolite of Methotrexate. Methotrexate is a Folic acid (HY-16637) antagonist, widely used as an immunosuppressant. Methotrexate metabolite is an antimalarial agent that inhibits parasite growth under physiological folic acid conditions, with IC50 values of 446 nM and 812 nM against folic acid-sensitive strains and highly resistant strains, respectively. Methotrexate metabolite exhibits pharmacokinetic characteristics of rapid clearance and extensive metabolism, with a mean clearance rate of 1.9 l/kg/h and a mean terminal half-life of 51 minutes. Methotrexate metabolite is promising for research in the field of inflammation.
    Methotrexate metabolite
  • HY-108551
    MG-262 179324-22-2
    MG-262 (Z-Leu-Leu-LeuB(OH)2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS). MG-262 can be used for anti-cancer study.
    MG-262
  • HY-108860
    Oncaspar 130167-69-0 ≥99.0%
    Oncaspar (PEG-L-asparaginase; Pegasparaginase), a pegylated form of native Escherichia coli-derived L-asparaginase, breaks down the amino acid asparagine that are circulating in the bloodstream. Oncaspar plays an important role in acute lymphoblastic leukemia (ALL) through asparagine hydrolysis and activation of the integrated stress response (ISR) pathway.
    Oncaspar
  • HY-111179
    ML261 902523-58-4
    ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation.
    ML261
  • HY-111573
    KCL-286 1952276-71-9 98.93%
    KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist (EC50 = 1.9 nM). KCL-286 targets RARβ2 with good selectivity over RAR α (EC50 = 26 nM) and RAR γ (EC50 = 11 nM). KCL-286 activates RARβ2 in the injured neurons. KCL-286 induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation and extracellular matrix molecules. KCL-286 can modulate the expression of CSPGs by neuronal secretion of decorin which promotes myelination and aids axonal growth. KCL-286 can be studied in research for area such as spinal cord injury and traumatic nerve injury.
    KCL-286
  • HY-112256
    ACP-105 899821-23-9 98.92%
    ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC50s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively.
    ACP-105
  • HY-112629
    PDM2 688348-25-6 98.96%
    PDM2 is a selective, high-affinity aryl hydrocarbon receptor (AhR) antagonist with an Ki of 1.2±0.4 nM.
    PDM2
  • HY-112671
    CDDO-dhTFEA 1191265-33-4 99.64%
    CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB. CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats.
    CDDO-dhTFEA
  • HY-113248
    3-Nitro-L-tyrosine

    3-Nitro-L-tyrosine

    		621-44-3 99.89%
    3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
    3-Nitro-L-tyrosine
  • HY-114200
    Imrecoxib 395683-14-4 ≥99.0%
    Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect.
    Imrecoxib
  • HY-114974
    Rivenprost 256382-08-8 99.0%
    Rivenprost (ONO-4819; ONO-AE1-734) is a selective agonist for prostaglandin E receptor EP4 with Ki of 0.7 nM. Rivenprost exhibits hepatoprotective and bone anabolic effects.
    Rivenprost
  • HY-117666
    NSC668036 144678-63-7 ≥99.0%
    NSC668036 is a Dishevelled (Dvl) PDZ domain inhibitor with a Kd of 237 μM. NSC668036 blocks Wnt signaling by interrupting the Frizzled-Dvl interaction.
    NSC668036
  • HY-119720
    Neocryptotanshinone 109664-02-0 98.82%
    Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza, inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathways.
    Neocryptotanshinone
  • HY-120813
    ARN 077 1373625-34-3 99.82%
    ARN 077 is a potent and selective N-acylethanolamine acid amidase (NAAA) inhibitor with an IC50 of 7 nM for human NAAA. ARN 077 significantly increases palmitoyl ethanolamine (PEA) levels within the CNS and has broad antinociceptive activity in mice and rats.
    ARN 077
  • HY-121508
    (E/Z)-IT-603 292168-90-2 99.29%
    (E/Z)-IT-603 is a mixture of E-IT-603 and Z-IT-603 (IT-603). (E/Z)-IT-603 is also an IĸBα/c-Rel inhibitor. IT-603 is a c-Rel inhibitor with an IC50 of 3 μM. IT-603 has anti-tumor activity. (E/Z)-IT-603 is a promising modulator of T-cell responses in the context of graft-versus-host disease (GVHD) and malignant diseases.
    (E/Z)-IT-603
  • HY-12398A
    TEI-9648 173388-21-1 99.24%
    TEI-9648, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9648 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9648 also inhibits HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9648 has the potential for bone metabolism research.
    TEI-9648
  • HY-124071
    ACT-389949 1258417-54-7 99.96%
    ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders.
    ACT-389949
製品番号 製品名 / Synonyms Application Reactivity